Vitrolife AB
STO:VITR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (6.5), the stock would be worth kr162.85 (56% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.2 | kr104.7 |
0%
|
| 3-Year Average | 6.5 | kr162.85 |
+56%
|
| 5-Year Average | 8.4 | kr210.77 |
+101%
|
| Industry Average | 7.9 | kr197.9 |
+89%
|
| Country Average | 2 | kr49.68 |
-53%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
kr15.4B
|
/ |
Apr 2026
kr3.4B
|
= |
|
|
kr15.4B
|
/ |
Dec 2026
kr3.6B
|
= |
|
|
kr15.4B
|
/ |
Dec 2027
kr3.9B
|
= |
|
|
kr15.4B
|
/ |
Dec 2028
kr4.1B
|
= |
|
|
kr15.4B
|
/ |
Dec 2031
kr4.9B
|
= |
|
|
kr15.4B
|
/ |
Dec 2032
kr5.3B
|
= |
|
|
kr15.4B
|
/ |
Dec 2033
kr5.6B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Vitrolife AB
STO:VITR
|
14.1B SEK | 4.2 | -2.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 6.2 | 90 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 5.1 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 5.6 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 9.1 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 5.2 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 11.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.7 | 29.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 1.2 |
| Median | 2 |
| 70th Percentile | 4.4 |
| Max | 13 940.4 |
Other Multiples
Vitrolife AB
Glance View
Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.
